NL-OMON26435Not yet recruitingNot Applicable
Bosentan (Tracleer) in patients with Behçet's disease: a Pilot Study.
ErasmusMC0 sites20 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. BD patients classified according to the criteria according to the International study group for BD
- •2.BD patients not responding to their usual therapy (BDCAF > 20)
Exclusion Criteria
- •1.Age < 18 years.
- •2.Women who are pregnant, nursing, or planning pregnancy within 38 weeks after enrollment.
Investigators
Similar Trials
Completed
Phase 2
Bosentan (Tracleer®) in patients with Behçet*s disease: a Pilot Study.NL-OMON31428Academisch Medisch Centrum20
Completed
Phase 2
Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.Other Specified Congenital Anomalies of HeartTricuspid AtresiaHypoplastic Left Heart SyndromeNCT01292551Rigshospitalet, Denmark75
Completed
Not Applicable
Bosentan, an endothelin-receptor antagonist, in the treatment of pulmonary hypertension in severe chronic obstructive pulmonary disease: a prospective, double-blind, placebo-controlled trialChronic obstructive pulmonary diseaseRespiratoryISRCTN98252311niversity Hospital Basel (USB) (Switzerland)24
Completed
Not Applicable
Bosentan improves clinical Outcome of adults with congenital heart disease or mitral valve lesions who undergo CArdiac surgeryaangeboren hartafwijkingopen hart operatie risico1004697310007510NL-OMON36241Academisch Medisch Centrum110
Not yet recruiting
Not Applicable
The role of Bosentan in fontan patients: improvement of aerobic capacity.aerobic capacity (peak V’O2)quality of life prevalence of arrhythmiasprevalence of protein losing enteropathyNL-OMON24216none40